Efficacy of JAK inhibitors in Ulcerative Colitis

Janus kinase [JAK] inhibitors are a completely novel therapy for the treatment of patients with immune-mediated inflammatory disorders. The oral formulation of tofacitinib has recently been approved for the treatment of moderate-to-severe ulcerative colitis. In the placebo-controlled OCTAVE programme, tofacitinib proved to be efficacious for both inducing and maintaining clinical remission, and this both in anti-tumour necrosis factor-naïve and exposed patients. Several other anti-JAK inhibitors are currently explored. This review summarises the available efficacy data from all anti-JAK inhibitors in ulcerative colitis.

Publication year:2020

BOF-keylabel:yes

IOF-keylabel:yes

BOF-publication weight:3

CSS-citation score:1

Authors from:Higher Education

Accessibility:Open